Literature DB >> 27387962

Metastatic surgery in testis cancer.

David Pfister1, Friederike Haidl, Pia Paffenholz, Axel Heidenreich.   

Abstract

PURPOSE OF REVIEW: In testis cancer, prognosis is excellent even in metastatic disease. Treatment and timing of patients with multiple metastatic deposits can be challenging. This review was performed to underline the current guideline recommendations. RECENT
FINDINGS: Depending on the primary histology, the indication of further surgical resections differ. In seminoma, resídual tumor resections are performed according to the results of a flouoro-deoxy-D-glucose-PET. Positive results must be considered critically, and to recent results it is advisable to first repeat flouoro-deoxy-D-glucose-PET to avoid overtreatment. In nonseminomatous germ cell cancer, complete remissions in good prognosis patients are followed and can be spared from surgery. All other patients still need to undergo postchemotherapy retroperitoneal lymph node dissection. In bone metastases, significant histology is found in 80% so that one should go for complete resection. In liver metastases, resections can be performed according to the histology in the retroperitoneum. Both resections, including vessel replacement, are usually performed in one session underlining the complex multidisciplinary approach. Pulmonal metastases, at least in one lobe, need to be resected. Brain metastases are rare with no standard treatment recommendation.
SUMMARY: Every patient should be presented in a multidisciplinary tumor board. Surgical interventions should be done in tertiary referral centers to achieve the best oncologic outcome and reduced morbidity.

Entities:  

Mesh:

Year:  2016        PMID: 27387962     DOI: 10.1097/MOU.0000000000000324

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  1 in total

1.  Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis.

Authors:  Mierxiati Abudurexiti; Yao Zhu; Ding-Wei Ye
Journal:  Mol Clin Oncol       Date:  2020-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.